Publicação oficial da Call 13 da Iniciativa Europeia Medicamentos Inovadores (IMI-2) | Participe nos webinars!

 

A Iniciativa Medicamentos Inovadores (IMI-2) acaba de abrir oficialmente a sua Call 13, concurso em 2 fases, com 15 tópicos para financiamento de projetos:

• Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
• Genome-environment interactions in inflammatory skin disease
• The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
• Mitochondrial dysfunction in neurodegeneration
• Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative
• A sustainable European induced pluripotent stem cell platform
• Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
• Human tumour microenvironment immunoprofiling
• ConcePTION – Continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
• Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
• Translational safety biomarker pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
• Pilot programme on a Clinical Compound Bank for Repurposing: Cardiovascular diseases and diabetes
• Pilot programme on a Clinical Compound Bank for Repurposing: Respiratory diseases
• Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases
• Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases

A primeira fase deste concurso termina a 28 de fevereiro de 2018.

Para esclarecer potenciais candidatos e promover networking entre os mesmos, a IMI-2 realizará uma série de webinars sobre os tópicos e aspetos transversais deste concurso.

Lembramos abaixo as datas e os horários (à hora de Bruxelas – Central European Time, CET) dos webinars agendados:

27/11, 15:00: Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative

1/12, 10:30: Human tumour microenvironment immunoprofiling

4/12, 10:30: Mitochondrial dysfunction in neurodegeneration

4/12, 15:00: Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease

6/12, 10:30: Pilot programme on a clinical compound bank for repurposing (includes the following topics: cardiovascular diseases and diabetes; respiratory diseases; neurodegenerative diseases; rare/orphan diseases)

7/12, 15:00: IMI rules & procedures

7/12, 10:00: Opportunities for SMEs in IMI2 – Call 13

11/12, 10:30: A sustainable European induced pluripotent stem cell platform

11/12, 15:00: CONCEPTION – continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now

12/12, 15:00: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system

14/12, 10:30: Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice

14/12, 15:00: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches

15/12, 10:30: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use

15/12, 15:00: Genome-environment interactions in inflammatory skin disease

Não perca esta oportunidade de contactar e de colocar diretamente as suas perguntas junto da IMI-2.

Estes webinars são gratuitos, mas requerem a inscrição prévia aqui.

Publicado em 30.11.2017